logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: cancer
Load new posts () and activity
Like Reblog Comment
show activity (+)
review 2018-10-20 17:43
Raw, unfiltered, and achingly honest
When Breath Becomes Air - Paul Kalanithi,Abraham Verghese

When Breath Becomes Air by Paul Kalanithi is a posthumous memoir/biography from a man who was both in the prime of his life and the beginning of what promised to be an illustrious career as a neurosurgeon and neuroscientist. The terminal lung cancer which was already making its way through his spinal column wasn't part of the plan...and yet Paul chose to meet this challenge head-on as a way to understand and learn how the inevitability of death can be explored by those shepherding the way. How does the mind and brain (seen as two separate entities here) play a role in this? He first approached this topic through the lens of literature which he had always been interested in (hence the beginning of the book which would eventually be published after his death) but he then moved on to his direct experience as a doctor and then as a patient. Paul was interested in the bigger picture of what exactly death means and he kept trying to parse it out by asking, "Where did biology, morality, literature, and philosophy intersect?" (pg 41). He didn't shy away from the ugly underbelly of cancer treatment and how it's seen from both a medical professional's standpoint (best practices, proven remedies, etc) and the one receiving the care (uncertainty, despair, anger, and frustration to name a few). Facing mortality and asking the tough questions are the overarching themes of When Breath Becomes Air but this is also a quiet story about a man coming to terms with the fact his life was about to end. I don't want to give away all of the details because I really think you should read this one if you never read another book about death (although why stop here?). I didn't know if I'd be able to continue it at several points (there were tears) because it mirrors so much of what my dear friend, Jessica, went through during her battle with cancer. But I am happy that I persevered. 10/10

 

This quote blew my mind because I feel I'm constantly justifying to people why I do the work that I do even though some of it doesn't compensate me at all (the blog) and the one that does is probably never going to make me financially solvent (children's librarian). Looking at the bigger picture is hard if you are cutting out the crucial bits like death which comes for us all.

Indeed, this is how 99 percent of people select their jobs: pay, work, environment, house. But that's the point. Putting lifestyle first is how you find a job - not a calling. - pg 68-69

If I remember correctly this was a quote from Paul's wife and I think it perfectly encapsulates why this is such an important book. It's why I've read and reviewed so many books around this topic over the past year. 

Paul confronted death - examined it, wrestled with it, accepted it - as a physician and a patient. He wanted to help people understand death and face their mortality. Paul's decision not to avert his eyes from death epitomizes a fortitude we don't celebrate enough in our death-avoidant culture. - pg 215

Side note of interest (at least to me): Lucy, Paul's widow, found love again with a recently widowed father of two...who's spouse also wrote a book about her journey of dying. That book is The Bright Hour: A Memoir of Living and Dying by Nina Riggs and yes it's totally going on my TRL.

 

What's Up Next: Being Mortal: Medicine and What Matters in the End by Atul Gawande

 

What I'm Currently Reading: The Bear and the Nightingale by Katherine Arden

 

Source: readingfortheheckofit.blogspot.com
Like Reblog Comment
text 2018-09-15 07:31
Pancreatic Cancer Diagnostic Industry Market

The Global and Chinese Pancreatic Cancer Diagnostic Industry, 20132023 Market Research Report is a professional and indepth study on the current state of the global Pancreatic Cancer Diagnostic industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pancreatic Cancer Diagnostic manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 20132018 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Pancreatic Cancer Diagnostic industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 20182023 market development trends of Pancreatic Cancer Diagnostic industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Pancreatic Cancer Diagnostic Industry before evaluating its feasibility. Overall, the report provides an indepth insight of 20132023 global and Chinese Pancreatic Cancer Diagnostic industry covering all important parameters.

Any special requirements about this report, please let us know and we can provide custom report.

Source: www.qandqmarketresearch.com
Like Reblog Comment
text 2018-08-30 10:40
Kidney Cancer Drugs Market Analysis, Strategies and Forecasts, 2015 To 2025

The global Kidney Cancer Drugs Market is expected to grow at a healthy rate during the forecast period. Renal Cell Carcinoma (RCC) is one of the most common types of urologic tumors in adults. It accounts for around 2% of all new cases of tumor in humans. However, clinical removal of the cancerous cells is vital for a total cure from the disease. Until last few decades, surgical removal of kidneys. This treatment method was later replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

 

Early diagnosis is vital when it comes to treatment of this disease. Various treatment methods such as immune modulation therapy, Vascular Endothelial Growth Factor (VEGF) inhibitors, and cytokine therapy are utilized to cure the tumor. Additionally, variety of drugs are available for the treatment of diseases like kidney cancer when identified at an early stage. Hence, governments and healthcare organizations are engaging in awareness drives for early detection. This factor is anticipated to bode well for market over the forecast period.

 

Prevalence of RCC is projected to increase in near future owing to factors such as rising obesity and number of smokers and reduced physical activities due to changing lifestyle. Symptoms of renal cancer are similar to several other kidney disorders, which make it difficult to get detected. This factor also reduces survival rate among patients who are mostly diagnosed with RCC during routine checkups for some other medical conditions.

 

The global market is majorly driven by changing lifestyle of the global population. Predominance of lifestyle influenced diseases is one of the major driving factors. Excessive smoking and alcohol consumption lead to chronic diseases including different types of cancer. This factor is expected to fuel the market for kidney cancer medicine in the forthcoming years. Rising geriatric population prone to chronic diseases is projected to propel demand for these medicines in the years to come.

 

Preference for these drugs over targeted remedies is anticipated to bode well for growth of the global market over the forecast period. Also, availability of a limited number of approved drugs is one of the factors assisting product demand. Kidney cancer medicines are one of the life protracting treatment options available for patients suffering from advanced stage of metastatic tumor. Furthermore, occurrence of this disease is expected to be higher in developed countries compared to developing regions. This factor is expected to impel demand for these medicines from regions like North America and Europe.

 

Browse Details of Report @ https://www.hexaresearch.com/research-report/kidney-cancer-drugs-market

 

However, high price of branded drugs is projected to hinder overall growth over the forecast period. As a result, generic medicine variants are preferred over their branded counterparts. This factor is anticipated to obstruct market development in the forthcoming years.

 

Primary branded medicines in the global kidney cancer drugs market include Nexavar (Sorafenib), Inlyta (Axitinib), Avastin (Bevacizumab), Votrient (Pazopanib), Afinitor (Everolimus), Sutent (Sunitinib), Torisel (Temsirolimus), and Proleukin (Interlukin-2/Aldesleukin). Sutent was one of the highly demanded medicine types in the past. However, drugs like Votrient are also anticipated to witness substantial demand over the forecast period. At present, most potential drugs are in phase II and III clinical trials. Medicines such as Keytruda, AGS-003, Opdivo, Cabozantinib, and Dovitinib are projected to be commercialized and launched in the years to come.

 

North America accounted for a prominent market share in the past. High prevalence of kidney cancer and other kidney diseases is the primary growth driver. Additionally, U.S. is the largest market for pharmaceuticals. This factor is anticipated to bode well for the growth of the regional demand for kidney cancer drugs. Asia Pacific is estimated to witness significant growth over the forecast period. Lower cost of drug production, high disease prevalence, and rising awareness among healthcare professionals as well as consumers are projected to drive regional growth in the forthcoming years.

 

The global market is highly consolidated and displays high competition among key participants. Major pharmaceutical giants in the market include Pfizer Inc.; Bayer Pharma AG; GlaxoSmithKline Plc; Hoffman-La Roche; and Novartis AG. Major companies are capitalizing heavily on research and development and adopting strategies like collaborations, new product launches, business expansions, and innovation to uphold their market share.

 

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-industry

Like Reblog Comment
text 2018-08-23 09:00
Colon and Rectal Cancer Drugs Market Opportunity Analysis, 2018 – 2026

Colon and rectal cancer are often grouped together, as they have many common features. Rate of colorectal cancer is increasing among the millennials in the U.S. The American Cancer Society (ACS) estimates that there will be around 97,220 new cases of colon cancer and around 43,030 new cases of rectal cancer registered in the U.S. in 2018. Moreover, owing to increasing risk of colorectal cancer, in May 2018, ACS updated their guidelines for colorectal cancer screenings and recommended to start colorectal cancer screening at the age of 45 rather than at the age of 50.

 

Click To Continue Reading on Colon and Rectal Cancer Drugs Market

 

Increasing incidence and prevalence of colon and rectal cancer, worldwide and increasing research and development studies for colorectal cancer treatment is expected to drive growth of colon and rectal cancer market in the near future. For instance, according to February 2018 data findings of the American Cancer Society (ACS), colorectal cancer is the third most common cancer diagnosed in both men and women in the U.S.

 

Moreover, according to the Center for Disease Control and Prevention (CDC), in 2014, around 139,992 people in the U.S. were diagnosed with colorectal cancer, including 73,396 men and 66,596 women. Among which, around 51,651 people in the U.S. died due to colorectal cancer, including 27,134 men and 24,517 women. Furthermore, according to 2012 data findings of the World Health Organization (WHO), colorectal cancer is the third most common cancer in men (746,000 cases, 10.0% of the total) and the second most common in women (614,000 cases, 9.2% of the total) worldwide, in 2012. Furthermore, around 55% of these cases occurred in developed regions.

Increasing number of research and development (R&D) studies by government and private healthcare organizations is also fueling growth of colon and rectal cancer drugs market. For instance, the American Cancer Society (ACS) spend US$ 54 million on colon and rectal cancer research involving 92 research grants, till March 2018.

 

Lack of development in the neoadjuvant/adjuvant pipeline agents for the treatment of high risk colorectal cancer resulted in slower growth of colon and rectal cancer drugs market. For instance, according to the data published in the National Center for Biotechnology Information (NCBI) in April 2016, there is lack of clinical trials of systemic adjuvant, neoadjuvant, and perioperative chemotherapy for the treatment of colorectal liver metastases (CRLM). These offers lucrative opportunity for the key players to develop new treatment therapy using neoadjuvant agents for resected patients.

 

On the basis of region, the global colon and rectal cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in the colon and rectal cancer drugs market, followed by Europe. This is owing to increasing incidence rate of colorectal cancer in these regions. According to the World Cancer Research Fund International, in 2012, Republic of Korea had the highest rate of colorectal cancer, followed by Slovakia and Hungary. Furthermore, since few years, large number of colorectal cancer incidences were registered in Oceania and Europe region, while it shows lowest incidence rates in Africa and Asia region.

 

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2019 

 

Key Vendors:

Amgen Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo Company, Merck KGaA, Novartis International AG, Sirtex Medical Limited, Sanofi S.A. Sorrento Therapeutics, and Takeda Pharmaceutical Company Ltd.

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

Like Reblog Comment
text 2018-07-06 13:32
Peptide Cancer Vaccine Market Global Insights, 2018-2026

Peptide cancer vaccines aids to elicit and expand tumor-specific T-cells capable of controlling or eradicating tumor. This vaccine consists of one or more short or long amino acid sequences as tumor antigens, combined with vaccine adjuvant. In the recent past, results of clinical trials performed using peptide cancer vaccine had exhibited negative outcomes. So, researchers in the peptide vaccine have considered this as outdated therapy and declared it as no longer viable for cancer treatment. However, increasing progress in understanding critical role of immune adjuvants, modes of vaccine administration, and T cell dynamics has led to re-emergence of this approach for treating malignant disorders.

Click To Continue Reading on Peptide Cancer Vaccine Market

North America market accounted for the largest share in the global peptide cancer vaccine market, followed by Europe market in 2016. 

Furthermore, advantages involved in the preparation and usage of peptide vaccine are easy to synthesize, cost-effective, easy to prepare, and its application in clinical practice, flexibility in changing antigen, and lower risk of antigen-induced anaphylaxis are expected to foster growth of the peptide cancer vaccine market in the near future. Therefore, owing to these advantages, manufacturers are focusing on research, to develop peptide cancer vaccines. For instance, in April 2018, Boston Biomedical, Inc. involved in next generation cancer therapeutics, initiated dosing of the first patient in each of two clinical studies to evaluate the results of its affectability by using DSP-7888, an investigational cancer peptide vaccine. 

According to a National Cancer Institute, 2016, in the U.S., it was estimated that 16.8 million new cases of cancer were diagnosed with an approximate 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024. Furthermore, the World Health Organization (WHO) reported around 14 million cases of cancer and 8.2 million deaths caused by the disease in 2012. Among these, the common cases pertained to lung, colorectal, prostate, cervical, and breast cancer, which significantly has increased demand for peptide vaccines, in turn aiding in growth of the global peptide cancer vaccine market.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1634

Key Vendors:

 TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Antigen Express, Immatics Biotechnologies, Immatics, Immune Design, Immunomedics, Galena Biopharma, Generex Biotechnology Corporation, and Ultimovacs.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
 #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

More posts
Your Dashboard view:
Need help?